BTK and B-cell chronic lymphocytic leukemia: The new-generation BTKi currently used to treat CLL include acalabrutinib, zanubrutinib, and tirabrutinib which have higher BTK selectivity and lower/no inhibitory effect on EGFR, TEC, ITK, etc.